SAN DIEGO, Aug. 1, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded hashish firm in america, introduced immediately that its portfolio firm Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical firm, has accomplished a share alternate supply with TYG Options Corp. (OTC:TYYG). The closing of this transaction marks an vital step in making Kannalife the one publicly traded firm within the cannabinoid therapeutics house with an unique license to a U.S. authorities patent from the Nationwide Institutes of Well being (“NIH”).
“We’re thrilled to announce the completion of this share alternate settlement,” mentioned Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Our firm was an early investor in Kannalife, which has developed and patented particular cannabinoid-like molecules to create a focused method to deal with medical circumstances. We imagine that Kannalife’s highly effective portfolio of IP units the corporate aside in an more and more aggressive cannabinoid pharmaceutical market area.”
Kannalife Sciences presently holds two licenses with NIH. The primary, an unique license for the commercialization of U.S. Patent #6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants”(the “‘507 Patent”), to analysis and develop novel cannabinoid-based therapeutics to deal with hepatic encephalopathy (HE); and the second, a non-exclusive license beneath the identical ‘507 Patent to deal with power traumatic encephalopathy (CTE).
“The completion of our share alternate transaction with TYYG has introduced us to a different start line within the firm’s historical past – now as a publicly traded firm. We now discover ourselves in the course of a really thrilling, resurgent and sizzling biotechnology house, coupled with burgeoning investor curiosity in ‘something hashish,’” Kannalife Sciences CEO Dean Petkanas mentioned. “The transaction with TYYG permits us to look towards the longer term as a publicly traded firm and proceed our analysis into creating disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related illnesses.”
Additional, Kannalife has developed its personal patented molecules led by KLS-13019 and was not too long ago awarded U.S. Patent #9,611,213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy.” These cannabidiol-derived new chemical entities (NCEs) are meant to advance a number of the medical advantages of CBD whereas enhancing upon a number of the pharmacokinetic limitations of CBD. In line with a February 10, 2016 publication in the American Chemical Society, KLS-13019 was discovered to be 50-fold stronger as a neuroprotectant and >400-fold safer than cannabidiol (CBD).
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier hashish and hemp business innovators, leveraging our group of pros to supply, consider and buy value-added corporations and merchandise, whereas permitting them to maintain their integrity and entrepreneurial spirit. We try to create consciousness inside our business, develop environmentally-friendly, economically sustainable companies, whereas rising shareholder worth. For particulars on Medical Marijuana, Inc.’s portfolio and funding corporations, go to www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s company video, click here.
Shareholders and shoppers are additionally inspired to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
About Kannalife Sciences, Inc. – A Phyto-Medical Firm™
Kannalife Sciences, Inc. is a phyto-medical firm concerned within the analysis and growth of novel therapeutic brokers designed to be neuroprotectants and immuno-modulators. Kannalife is presently conducting analysis and growth on the Pennsylvania Biotechnology Heart in Doylestown, PA, for goal drug candidates to deal with Hepatic Encephalopathy (“HE”) and Power Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress-related illnesses that have an effect on cognitive and behavioral features. For extra info, go to www.kannalife.com.
This press launch might include sure forward-looking statements and data, as outlined throughout the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934, and is topic to the Protected Harbor created by these sections. This materials incorporates statements about anticipated future occasions and/or monetary outcomes which can be forward-looking in nature and topic to dangers and uncertainties. Such forward-looking statements by definition contain dangers, uncertainties and different elements, which can trigger the precise outcomes, efficiency or achievements of Medical Marijuana, Inc. to be materially completely different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements haven’t been evaluated by the FDA and will not be meant to diagnose, deal with or treatment any illness.
Medical Marijuana, Inc. doesn’t promote or distribute any merchandise which can be in violation of america Managed Substances Act (US.CSA). These corporations do develop, promote, and distribute hemp-based merchandise and are concerned with the federally authorized distribution of medical marijuana-based merchandise inside sure worldwide markets. Cannabidiol is a pure constituent of hemp oil.
Public Relations Contact:
Chief Government Officer CMW Media